Human & Experimental Toxicology http://het.sagepub.com/
The protective effect of recombinant human erythropoietin against cisplatin-induced renal and hepatic dysfunctions in Wistar rats Hamid Nasri Hum Exp Toxicol published online 5 February 2014 DOI: 10.1177/0960327113489051 The online version of this article can be found at: http://het.sagepub.com/content/early/2014/02/04/0960327113489051
Published by: http://www.sagepublications.com
Additional services and information for Human & Experimental Toxicology can be found at: Email Alerts: http://het.sagepub.com/cgi/alerts Subscriptions: http://het.sagepub.com/subscriptions Reprints: http://www.sagepub.com/journalsReprints.nav Permissions: http://www.sagepub.com/journalsPermissions.nav
>> OnlineFirst Version of Record - Feb 5, 2014 What is This?
Downloaded from het.sagepub.com at St Petersburg State University on February 13, 2014
Letter to the Editor
The protective effect of recombinant human erythropoietin against cisplatin-induced renal and hepatic dysfunctions in Wistar rats
Human and Experimental Toxicology 1–2 ª The Author(s) 2014 Reprints and permission: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/0960327113489051 het.sagepub.com
Hamid Nasri
I read with interest the recently published article by Rjiba-Touati and colleagues, entitled ‘‘The protective effect of recombinant human erythropoietin against cisplatin-induced renal and hepatic dysfunctions in Wistar rats,’’ in the esteemed journal of Human & Experimental Toxicology.1 The study has focused to explore the protective effect of recombinant human erythropoietin against cisplatin-induced renal and liver dysfunctions. They suggest that erythropoietin treatment restored body weight, organ weight, and organ ratio as well as serum biochemical parameters changed due to cisplatin exposure.1 I would like to mention a few points about cisplatininduced nephrotoxicity. Recently, I observed that estrogen abolished protective effect of erythropoietin against cisplatin nephrotoxicity in ovariectomized rats.2 In another experimental study, my colleagues and I found that L-arginine had protective effect against cisplatin nephrotoxicity in male rats; however, it promoted damage in female subjects. We described a gender-related difference in rat model of cisplatin nephrotoxicity.3 Since, the role of gender in cisplatin nephrotoxicity is not well known, we recently conducted a study on rat model of cisplatin nephrotoxicity and observed that losartan prevented cisplatin nephrotoxicity in male subjects, but it induced tubular damage in female subjects, which might be related to the rennin angiotensin system receptors in the kidneys.4 Additionally, we recently reported that vitamin E, vitamin C, or losartan had no ameliorative effects against cisplatin nephrotoxicity in the presence of estrogen in ovariectomized rats,5 which is in agreement with our previous findings. Kidney protective effect of erythropoietin was also shown in our previous studies.6–8 Therefore, it is well found that there is a sex difference in the cisplatin nephrotoxicity in rats. It is well known that some conditions that lead to chronic kidney disease are also sex
related.9 The studies published regarding sex difference in cisplatin-induced nephrotoxicity are rare and needs to explore the mechanisms involved especially for gender differences.10–13 In this regard, to better understand the factor of gender difference in cisplatin nephrotoxicity, more experimental or clinical studies are suggested. References 1. Rjiba-Touati K, Ayed-Boussema I, Belarbia A, Guedri Y, Zakhama A, Achour A, et al. The protective effect of recombinant human erythropoietin against cisplatin-induced renal and hepatic dysfunctions in Wistar rats. Hum Exp Toxicol. Epub ahead of print 30 October 2012. DOI: 10.1177/0960327111428957. 2. Pezeshki Z, Nematbakhsh M, Mazaheri S, Eshraghi-Jazi F, Talebi A, Nasri H, et al. Estrogen abolishes protective effect of erythropoietin against cisplatin-induced nephrotoxicity in ovariectomized rats. ISRN Oncol 2012; 2012: 890310. 3. Eshraghi-Jazi F, Nematbakhsh M, Nasri H, Talebi A, Haghighi M, Pezeshki Z, et al. The protective role of endogenous nitric oxide donor (L-arginine) in cisplatin-induced nephrotoxicity: gender related differences in rat model. J Res Med Sci 2011; 16(11): 1389–1396. 4. Haghighi M, Nematbakhsh M, Talebi A, Nasri H, Ashrafi F, Roshanaei K, et al. The role of angiotensin II Department of Nephrology, Division of Nephropathology, Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran Corresponding author: Hamid Nasri, Department of Nephrology, Division of Nephropathology, Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran. Email: [email protected]
Downloaded from het.sagepub.com at St Petersburg State University on February 13, 2014
2
Human and Experimental Toxicology
5.
6.
7. 8. 9.
receptor 1 (AT1) blockade in cisplatin-induced nephrotoxicity in rats: gender related differences. Ren Fail 2012; 34(8): 1046–1051. Nematbakhsh M, Pezeshki Z, Eshraghi-Jazi F, Ashrafi F, Nasri H, Talebi A, et al. Vitamin E, vitamin C, or losartan is not nephroprotectant against cisplatin-induced nephrotoxicity in presence of estrogen in ovariectomized rat model. Int J Nephrol 2012; 2012: 284896. Rafieian-Kopaei M, Nasri H, Nematbakhsh M, Baradaran A, Gheissari A, Rouhi H, et al. Erythropoietin ameliorates gentamicin-induced renal toxicity: a biochemical and histopathological study. J Nephropathol 2012; 1(2): 109–116. Kadkhodaee M. Erythropoietin; bright future and new hopes for an old drug. J Nephropathol 2012; 1(2): 81–82. Tavafi M. Inhibition of gentamicin induced renal tubular cell necrosis. J Nephropathol 2012; 1(2): 83–86. Solati M and Mahboobi HR. Paraoxonase enzyme activity and dyslipidemia in chronic kidney disease patients. J Nephropathol 2012; 1(3): 123–125.
10. Nematbakhsh M, Ashrafi F, Safari T, Talebi A, Nasri H, Mortazavi M, et al. Administration of vitamin E and losartan as prophylaxes in cisplatin-induced nephrotoxicity model in rats. J Nephrol 2012; 25(3): 410–417. 11. Ashrafi F, Haghshenas S, Nematbakhsh M, Nasri H, Talebi A, Eshraghi-Jazi F, et al. The role of magnesium supplementation in cisplatin-induced nephrotoxicity in a rat model: no nephroprotectant effect. Int J Prev Med 2012; 3(9): 637–643. 12. Nematbakhsh M, Ashrafi F, Pezeshki Z, Fatahi Z, Kianpoor F, Sanei MH, et al. A histopathological study of nephrotoxicity, hepatoxicity or testicular toxicity: which one is the first observation as side effect of Cisplatin-induced toxicity in animal model. J Nephropathol 2012; 1(3): 190–193. 13. Nematbakhsh M, Talebi A, Nasri H, Safari T, Dolatkhah S, Ashrafi F, et al. Some evidence for sex based differences in cisplatin-induced nephrotoxicity in rats. Clin Exp Med Lett 2012; 53(1–229): 31.
Downloaded from het.sagepub.com at St Petersburg State University on February 13, 2014
The protective effect of recombinant human erythropoietin against cisplatin-induced renal and hepatic dysfunctions in Wistar rats Hamid Nasri Hum Exp Toxicol published online 5 February 2014 DOI: 10.1177/0960327113489051 The online version of this article can be found at: http://het.sagepub.com/content/early/2014/02/04/0960327113489051
Published by: http://www.sagepublications.com
Additional services and information for Human & Experimental Toxicology can be found at: Email Alerts: http://het.sagepub.com/cgi/alerts Subscriptions: http://het.sagepub.com/subscriptions Reprints: http://www.sagepub.com/journalsReprints.nav Permissions: http://www.sagepub.com/journalsPermissions.nav
>> OnlineFirst Version of Record - Feb 5, 2014 What is This?
Downloaded from het.sagepub.com at St Petersburg State University on February 13, 2014
Letter to the Editor
The protective effect of recombinant human erythropoietin against cisplatin-induced renal and hepatic dysfunctions in Wistar rats
Human and Experimental Toxicology 1–2 ª The Author(s) 2014 Reprints and permission: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/0960327113489051 het.sagepub.com
Hamid Nasri
I read with interest the recently published article by Rjiba-Touati and colleagues, entitled ‘‘The protective effect of recombinant human erythropoietin against cisplatin-induced renal and hepatic dysfunctions in Wistar rats,’’ in the esteemed journal of Human & Experimental Toxicology.1 The study has focused to explore the protective effect of recombinant human erythropoietin against cisplatin-induced renal and liver dysfunctions. They suggest that erythropoietin treatment restored body weight, organ weight, and organ ratio as well as serum biochemical parameters changed due to cisplatin exposure.1 I would like to mention a few points about cisplatininduced nephrotoxicity. Recently, I observed that estrogen abolished protective effect of erythropoietin against cisplatin nephrotoxicity in ovariectomized rats.2 In another experimental study, my colleagues and I found that L-arginine had protective effect against cisplatin nephrotoxicity in male rats; however, it promoted damage in female subjects. We described a gender-related difference in rat model of cisplatin nephrotoxicity.3 Since, the role of gender in cisplatin nephrotoxicity is not well known, we recently conducted a study on rat model of cisplatin nephrotoxicity and observed that losartan prevented cisplatin nephrotoxicity in male subjects, but it induced tubular damage in female subjects, which might be related to the rennin angiotensin system receptors in the kidneys.4 Additionally, we recently reported that vitamin E, vitamin C, or losartan had no ameliorative effects against cisplatin nephrotoxicity in the presence of estrogen in ovariectomized rats,5 which is in agreement with our previous findings. Kidney protective effect of erythropoietin was also shown in our previous studies.6–8 Therefore, it is well found that there is a sex difference in the cisplatin nephrotoxicity in rats. It is well known that some conditions that lead to chronic kidney disease are also sex
related.9 The studies published regarding sex difference in cisplatin-induced nephrotoxicity are rare and needs to explore the mechanisms involved especially for gender differences.10–13 In this regard, to better understand the factor of gender difference in cisplatin nephrotoxicity, more experimental or clinical studies are suggested. References 1. Rjiba-Touati K, Ayed-Boussema I, Belarbia A, Guedri Y, Zakhama A, Achour A, et al. The protective effect of recombinant human erythropoietin against cisplatin-induced renal and hepatic dysfunctions in Wistar rats. Hum Exp Toxicol. Epub ahead of print 30 October 2012. DOI: 10.1177/0960327111428957. 2. Pezeshki Z, Nematbakhsh M, Mazaheri S, Eshraghi-Jazi F, Talebi A, Nasri H, et al. Estrogen abolishes protective effect of erythropoietin against cisplatin-induced nephrotoxicity in ovariectomized rats. ISRN Oncol 2012; 2012: 890310. 3. Eshraghi-Jazi F, Nematbakhsh M, Nasri H, Talebi A, Haghighi M, Pezeshki Z, et al. The protective role of endogenous nitric oxide donor (L-arginine) in cisplatin-induced nephrotoxicity: gender related differences in rat model. J Res Med Sci 2011; 16(11): 1389–1396. 4. Haghighi M, Nematbakhsh M, Talebi A, Nasri H, Ashrafi F, Roshanaei K, et al. The role of angiotensin II Department of Nephrology, Division of Nephropathology, Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran Corresponding author: Hamid Nasri, Department of Nephrology, Division of Nephropathology, Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran. Email: [email protected]
Downloaded from het.sagepub.com at St Petersburg State University on February 13, 2014
2
Human and Experimental Toxicology
5.
6.
7. 8. 9.
receptor 1 (AT1) blockade in cisplatin-induced nephrotoxicity in rats: gender related differences. Ren Fail 2012; 34(8): 1046–1051. Nematbakhsh M, Pezeshki Z, Eshraghi-Jazi F, Ashrafi F, Nasri H, Talebi A, et al. Vitamin E, vitamin C, or losartan is not nephroprotectant against cisplatin-induced nephrotoxicity in presence of estrogen in ovariectomized rat model. Int J Nephrol 2012; 2012: 284896. Rafieian-Kopaei M, Nasri H, Nematbakhsh M, Baradaran A, Gheissari A, Rouhi H, et al. Erythropoietin ameliorates gentamicin-induced renal toxicity: a biochemical and histopathological study. J Nephropathol 2012; 1(2): 109–116. Kadkhodaee M. Erythropoietin; bright future and new hopes for an old drug. J Nephropathol 2012; 1(2): 81–82. Tavafi M. Inhibition of gentamicin induced renal tubular cell necrosis. J Nephropathol 2012; 1(2): 83–86. Solati M and Mahboobi HR. Paraoxonase enzyme activity and dyslipidemia in chronic kidney disease patients. J Nephropathol 2012; 1(3): 123–125.
10. Nematbakhsh M, Ashrafi F, Safari T, Talebi A, Nasri H, Mortazavi M, et al. Administration of vitamin E and losartan as prophylaxes in cisplatin-induced nephrotoxicity model in rats. J Nephrol 2012; 25(3): 410–417. 11. Ashrafi F, Haghshenas S, Nematbakhsh M, Nasri H, Talebi A, Eshraghi-Jazi F, et al. The role of magnesium supplementation in cisplatin-induced nephrotoxicity in a rat model: no nephroprotectant effect. Int J Prev Med 2012; 3(9): 637–643. 12. Nematbakhsh M, Ashrafi F, Pezeshki Z, Fatahi Z, Kianpoor F, Sanei MH, et al. A histopathological study of nephrotoxicity, hepatoxicity or testicular toxicity: which one is the first observation as side effect of Cisplatin-induced toxicity in animal model. J Nephropathol 2012; 1(3): 190–193. 13. Nematbakhsh M, Talebi A, Nasri H, Safari T, Dolatkhah S, Ashrafi F, et al. Some evidence for sex based differences in cisplatin-induced nephrotoxicity in rats. Clin Exp Med Lett 2012; 53(1–229): 31.
Downloaded from het.sagepub.com at St Petersburg State University on February 13, 2014
